Indian Lung Cancer Therapeutics Market size stood at around USD XX billion in 2019 and is projected to reach USD XX billion by 2028, exhibiting a CAGR of XX% during the forecast period.
India reflects the impact of industrialization and smoking trends on cancer in the community. After the initial erroneous impression of the rarity of lung cancer likely resulting from paucity in lung cancer. There were 57,795 new cases of lung cancer in 2012, which is projected to rise to 67,000 new cases annually by the year 2020. In India, a total of 67,795 new lung cancer cases occurred (5.9% of all cancers) in 2018, of which 48,698 (8.5%) occurred in males. Lung cancer caused 63,475 deaths, comprising 8.1% of all cancer-related deaths in India. In India, lung cancer constitutes 6.9% of all new cancer cases and 9.3% of all cancer related deaths. There were 53,728 new lung cancer cases among Indian males and 16,547 new lung cancer cases among Indian females. Atezolizumab is the first cancer immunotherapy to receive an approval in India for the first line treatment of extensive-stage small cell lung cancer (ES-SCLC).
The major factors driving the growth of this market are increasing incidence and prevalence of lung cancer, rapid growth in the aging population, and growing healthcare expenditure, high cost of lung cancer surgeries, growing demand for targeted therapies, presence of highly efficient drugs, increase in geriatric population, and rise in the prevalence of unhealthy lifestyles, the arrival of Nano medicine to treat lung cancer and the growing approvals in the lung cancer therapeutics market fuel the opportunities for the rise in the lung cancer therapeutics market in India.